2024 Outlook and Expectations for Global Pharma, Biopharma and Biotech
Duration: 60 minutes Join BI's global healthcare team as they discuss issues, expectations and key events anticipated in 2024 for Pharma, Biopharma and Biotech. Topics include regulatory change, capital allocation, growth and valuation, disease area trends and anticipated catalysts.
Speakers
John Murphy
Senior Research Analyst
Bloomberg Intelligence
John Murphy is a senior equity analyst at Bloomberg Intelligence focused on large-cap Pharma. Prior to joining Bloomberg in 2021 John was a partner at Arkle Associates, an independent healthcare advisory company, and before that spent the majority of his career in healthcare equity research at Goldman Sachs. Additional experience includes working in drug discovery in the pharmaceutical industry. He gained a D.Phil in Biochemistry at the University of York and a BSc.(Hons) in Applied Biology from the University of Hertfordshire.
Michael Shah
Senior Research Analyst
Bloomberg Intelligence
Michael Shah is a senior equity analyst on the healthcare team at Bloomberg Intelligence covering the biopharmaceutical sector. Prior to joining Bloomberg Intelligence, Michael joined the Bloomberg equity fundamentals team after graduating from the London School of Economics with a BSc in Accounting and Finance. He has been focused on the healthcare sector for more than ten years, initially assisting with on U.S and European Large Pharmaceuticals coverage before transitioning to European Biotech. Focus areas include cardio-metabolic, inflammatory and dermatological disease.
Max Nisen
Analyst
Bloomberg Intelligence
Max Nisen is a senior associate equity research analyst specializing in the pharmaceutical and biotechnology sector. Prior to joining Bloomberg Intelligence, Max was the founding health care columnist for Bloomberg Gadfly and later Bloomberg Opinion, where he wrote about the pharmaceutical industry, managed care, policy and public health. Before that, he covered business and financial news at Quartz and Business Insider. Max earned a bachelor’s degree in economics from Pomona College.
Leslie Yang
Analyst
Bloomberg Intelligence
Leslie is an analyst with BI in Hong Kong covering China biotech. Prior to joining Bloomberg, Leslie spent three years in healthcare companies and hospitals in New York, where she worked as a statistician in clinical trial design and data analysis. Leslie holds a Bachelor’s degree from Cornell University and a Master's degree from Columbia University.
Ann-Hunter Van Kirk
Senior Equity Research Analyst
Bloomberg Intelligence
Ann-Hunter Van Kirk is a Senior Equity Research Analyst at Bloomberg Intelligence covering the Biopharmaceutical sector with a focus on gene editing, animal health, neuroscience, generics, and eyecare companies. A.H. brings a long career of sell-side healthcare equity research experience from prior positions at Barclays, BMO Capital Markets, and Cantor Fitzgerald. Ms. Van Kirk holds a master's degree from the London School of Economics and two bachelor's degrees from Southern Methodist University with honors.
Jean Rivera Irizarry
Senior Equity Research Associate
Bloomberg Intelligence
Jean Rivera Irizarry is a senior equity research associate at Bloomberg Intelligence covering smid-cap Biotech, with a focus on protein degraders, oncology/autoimmune cell therapies, and neuroscience. Before joining Bloomberg Intelligence in 2022, Jean was finalizing his Ph.D. in neuropharmacology at Weill Cornell Medical School of Cornell University, while interning at a healthcare-focused hedge fund and leading an entrepreneurship course where students developed company pitches based on patented university technologies. Additional experiences include interning at Stellate Communications, securing competitive grant funding, and publishing multiple first-author papers in peer-reviewed scientific journals.